Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics Presents Updated NLG802 Results at the Immuno-Oncology 2019 World Congress
NLG802 , a prodrug of indoximod, produced significantly higher pharmacokinetic (PK) exposure in patients compared to molar equivalent of indoximod while maintaining encouraging safety profile Notable response in 5 th line pancreatic cancer patient re-challenged with chemotherapy after NLG802
View HTML
Toggle Summary NewLink Genetics Reports First Quarter 2019 Financial Results and Provides Clinical Activities Update
- Management to host conference call today at 4:30 p.m. ET AMES, Iowa , May 08, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the first quarter ended March 31, 2019 and provided an update on clinical activities.
View HTML
Toggle Summary NewLink Genetics to Participate in Upcoming Investor and Medical Conferences
AMES, Iowa , May 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor and medical conferences: Bank of America Merrill Lynch Global Health Care Conference 2019 on May 14-16 in Las Vegas Management will
View HTML
Toggle Summary NewLink Genetics to Host Its First Quarter 2019 Conference Call on May 8, 2019
AMES, Iowa , April 24, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will host its first quarter 2019 conference call and webcast at 4:30 PM ET on Wednesday, May 8, 2019, to discuss its first quarter financial results and provide an update of its clinical
View HTML
Toggle Summary NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
AMES, Iowa, April 02, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced results from a Phase 2 study of NLG207 , a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin, conducted in conjunction with The GOG Foundation, Inc.
View HTML
Toggle Summary NewLink Genetics Announces Clinical Trial Abstract Presentation at AACR Annual Meeting
AMES, Iowa , Feb. 27, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that a late-breaking abstract reporting results from a Phase 2 study of NLG207 , a nanoparticle formulation of the topoisomerase 1 inhibitor, camptothecin, has been accepted for poster
View HTML
Toggle Summary NewLink Genetics Reports Fourth Quarter, Year-End 2018 Financial Results and Provides Update for Clinical Programs
Management to Host Conference Call Today at 4:30 p.m. ET AMES, Iowa , Feb. 27, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) today reported consolidated financial results for the fourth quarter and year ended 2018, as well as progress in its clinical development programs. The
View HTML
Toggle Summary NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019
AMES, Iowa , Feb. 07, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019. The company has scheduled a conference call for 4:30 PM ET on the same day to
View HTML
Toggle Summary NewLink Genetics to Participate in the Immuno-Oncology 360° Conference
AMES, Iowa , Jan. 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the Company’s Chairman, CEO and Chief Scientific Officer, Charles J. Link, Jr , MD, will participate in the Immuno-Oncology 360 ° Conference (IO360 ° ) being held February 6 – 9, 2019 at
View HTML
Toggle Summary NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting
Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease (MRD) negativity rate of 86% and post-consolidation MRD negativity of 100% Safety data from this study indicate the combination treatment regimen was well
View HTML